Methods
Procedures
The Medical Dictionary for Regulatory Activities preferred terms were used to classify reported AEs. Rash (any type), photosensitivity conditions, pruritus, and dyspnea AEs were considered to be events of clinical interest, while AEs related to increased bilirubin were classified as events of special interest. The severity of laboratory abnormalities was determined according to the World Health Organization grading table and in accordance with the normal ranges of the clinical laboratory.
Patient-reported outcome (PRO) assessments were performed at scheduled clinic visits before all other study-related procedures, with patients independently completing the assessments electronically.
The Fatigue Severity Scale (FSS) is a nine-item scale. All nine items are combined to obtain a total FSS score, with higher values indicating a higher influence of fatigue on all items. The Center for Epidemiologic Studies Depression (CES-D) scale is a 20-item scale. The score (0-2) for each of the individual items is summed to produce a total score (0-60). The EuroQoL 5-Dimensions (EQ-5D) questionnaire Visual Analog Scale (VAS) uses a continuous score ranging from 0-100. The HCV Symptom and Impact Questionnaire version 4 (HCV-SIQv4) is a self-administered 33-item questionnaire: 29 questions on the severity and frequency of symptoms, three questions regarding the impact of these symptoms on work/school attendance, and one question regarding the impact of these symptoms on daily activities. Higher HCV-SIQv4 scores indicate worse symptom severity, more time missed from work/school, and more impairment in daily activities. Changes from baseline in HCV-SIQv4 overall body system score (OBSS) and individual body system scores (ie, for constitutional, gastrointestinal, psychiatric, neurocognitive, and integumentary symptoms) were calculated.
Statistical analysis
If superiority of both the 12-and 8-week simeprevir+sofosbuvir regimens was established against their respective HCs, non-inferiority of the 8-week versus the 12-week arm was to be assessed using a conventional confidence interval approach and a non-inferiority margin of 12%, such that if the lower limit of the 95% confidence interval for the difference in SVR rate 12 weeks after end of treatment (EOT; SVR12) between the two groups (8-week SVR12 rate -12-week SVR12 rate) exceeded -12% then non-inferiority of the 8-week versus the 12-week treatment regimen could be concluded.
For the statistical analysis of PRO results, a cumulative distribution function was drawn for FSS, CES-D, and EQ-5D VAS scores, as well as the HCV-SIQv4 OBSS and impact on daily life score (item 30) at different timepoints (scores at baseline and changes from baseline at Week 4, EOT, and follow-up assessments). Duration of clinically relevant deterioration or improvement in FSS scores (change of ≥1), worsening in CES-D scores (increase of ≥6 and increase of ≥10), decreased EQ-5D VAS scores (change ≤-10), and increased or decreased HCV-SIQv4 OBSS (change ≥10 points) from baseline were also summarized descriptively. Within the impact on daily life part of the HCV-SIQv4 questionnaire, the number of missed hours from work/school was displayed by means of descriptive statistics at each timepoint.
Results

Patient disposition and study population
At the time of this analysis, 50 of 310 patients (16%) had completed the study (ie, had reached Week 24 of follow-up after completing treatment) and 253 (82%) were still ongoing. Seven patients (2%) had discontinued from the study; six (2%) withdrew consent to continue and one (<1%) was lost to followup (Fig. 1) . A total of 99% of all patients had completed simeprevir+sofosbuvir treatment; 153 of 155 (99%) and 155 of 155 (100%) in the 12-and 8-week arms, respectively. Overall, 169 of 310 patients (55%) were male, 55 (18%) were Black/African American, and 48 (16%) were Hispanic. The median age was 56 years (range 19-70 years). Median baseline HCV RNA was 6.84 log 10 IU/mL (range 3.9-7.9 log 10 IU/mL). The majority of patients (232 of 310 [75%]) had HCV GT1a infection and, of these, 95 patients (41%) had a baseline NS3 Q80K polymorphism. Eight patients (3%) had NS3 baseline polymorphisms other than Q80K affecting simeprevir in vitro activity; seven patients had Q80R and one patient had D168E. The NS5B polymorphism S282T, which is known to affect sofosbuvir in vitro activity, was not observed at baseline. NS5A baseline polymorphisms were observed in 46 of 310 patients (15%) considering positions 28, 30, 31, 32, and 93 (Supporting Table 4 ).
A total of 115 of 155 patients (74%) and 103 of 155 patients (66%) were treatment naïve in the 12-and 8-week arms, respectively, while 40 (26%) and 52 (34%) were treatment experienced, respectively. (Table 1) .
Virological response
In the 12-week arm, 70 of 73 (96%) and 80 of 82 (98%) female and male patients achieved SVR 12 weeks after end of treatment (SVR12) versus 62 of 68 (91%) and 66 of 87 (76%), respectively, in the 8-week arm. Among White, Black, and African American patients, 117 of 120 (98%) and 29 of 31 (94%), respectively, achieved SVR12 in the 12-week arm versus 103 of 125 (82%) and 19 of 24 (79%) in the 8-week arm. All Hispanic and Latino patients (24 of 24 [100%]) achieved SVR12 in the 12-week arm versus 20 of 24 (83%) in the 8-week arm. While 106 of 310 patients (34%) overall had a body mass index (BMI) ≥30 kg/m 2 , no clear trend in SVR could be identified based on baseline BMI category. In the 12-week arm, 55 of 57 patients (96%) and 47 of 47 (100%) with BMI ≥30 or <25 kg/m 2 , respectively, achieved SVR12 versus 39 of 49 (80%) and 41 of 50 (82%) in the 8-week arm.
Among treatment-experienced patients in the 12-week arm, high SVR12 rates of 100% (eight of eight patients), 93% (13 of 14), 100% (two of two), and 94% (15 of 16) were observed in prior relapsers, prior non-responders, IFN-intolerant and other patients, respectively. In the 8-week arm, SVR12 rates were slightly lower in prior relapsers, prior non-responders, and other patients: 69% (nine of 13 patients), 70% (seven of 10) and 78% (14 of 18), respectively, whereas IFN-intolerant patients achieved SVR12 rates of 91% (10 of 11). Among non-responders, SVR12 rates of 100% (four of four), 88% (seven of eight) and 100% (two of two) were observed in partial responders, null responders, and unknown patients in the 12-week arm versus 100% (one of one), 60% three of five), and 75% (three of four), respectively, in the 8-week arm.
In the 12-week arm, similarly high SVR12 rates were observed in patients with and without baseline NS5A polymorphisms (96% [24 of 25 patients] and 97% [124 of 128 patients], respectively; Supporting Fig. 2 ). In the 8-week arm, SVR12 rates in patients with and without baseline NS5A polymorphisms were 71% (15 of 21 patients) and 84% (108 of 129 patients), respectively (Supporting Fig. 2) . Overall, the number of patients with baseline NS5A polymorphisms was limited and the numerical differences observed in the 8-week arm might be attributed to differences in other demographic and/or baseline disease factors. NS5A amino acid substitutions are fully susceptible to both simeprevir and sofosbuvir in vitro and therefore NS5A polymorphisms are not assumed to impact on the efficacy of a regimen containing both agents.
Treatment failure
In the 12-week arm, two of three GT1a patients (67%) who relapsed had baseline NS3 Q80K polymorphism. In the 8-week arm, 13 of 24 GT1a patients (54%) who relapsed had baseline NS3 Q80K polymorphism. In the 12-week arm, response at Week 4 was not predictive for relapse; all patients with HCV RNA <25 IU/mL detectable or ≥25 IU/mL achieved SVR12 (Table 3 ).
Safety
Low rates (≤8% in either arm) of rash, pruritus, photosensitivity, and dyspnea AEs were reported during the study (Table 4) . Increased bilirubin was reported as an AE in only one patient (1%) in each of the treatment arms, and there were no grade 3/4 AEs, serious AEs, or discontinuations of treatment due to increased bilirubin. No neutropenia or anemia AEs were reported in either arm (Table 4) . No grade 3/4 changes in bilirubin or hemoglobin laboratory parameters were reported in either treatment arm (Supporting Table 1 ). The observed increases in lipase and amylase levels were asymptomatic and transient, with the majority of these not reported as an AE (increased lipase AEs: two [1%] and one [<1%]; increased amylase AEs: one [<1%] and one [<1%] in the 12-and 8-week arms, respectively; Supporting Table 1 ). There were no reports of pancreatitis during the study.
Patient-reported outcomes
Baseline PRO scores indicated that patients were experiencing more severe fatigue, depressive symptoms, impairment in work and daily activities, and worse overall health-related quality of life versus normal reference values for the general population.
No increases in symptoms were reported during treatment in either arm, and significant reductions in pre-treatment symptom levels were observed after treatment ended, as assessed by the HCV-SIQv4 OBSS (Supporting Fig. 3A) . At the SVR12 timepoint (follow-up Week 12), both the 12-week and 8-week arms showed similar improvements (decreases) from baseline in the mean individual body system scores for the constitutional, psychiatric, and neurocognitive systems. For the gastrointestinal and integumentary systems there were notable differences between the treatment arms, with the 12-week arm showing improvements from baseline for both systems, but the 8-week arm showed a slight worsening (increase). However, the magnitude of the mean change from baseline was not clinically important for any individual body system score. Baseline individual body system scores are displayed in Supporting Table 5 . The ability to engage in daily activities did not change during treatment and improved slightly post-treatment in both arms (Supporting Fig. 3B) . In both arms, fatigue severity decreased from baseline throughout treatment and follow-up, with significant reductions in fatigue reported at follow-up visits (Supporting Fig. 3C ). Health-related quality of life improved relative to baseline throughout treatment and follow-up in both arms, with patients in the 12-week treatment arm who experienced an SVR12 reporting improvement in quality of life that was clinically important compared with those who did not achieve SVR12 (Supporting Table 3 ; Supporting Fig. 3D ). The severity of depressive symptoms did not change during treatment; in the 8-week arm, CES-D scores were lower than baseline at follow-up visits (Supporting Fig. 3E ). † Sustained virological response rates in IFN-intolerant patients were set to 5%, as no data with approved DAA regimens were available for this subgroup at the time of study design.
Supporting
‡ Patients who had received previous pegIFN-based therapy with no on-treatment HCV RNA data available or undetectable HCV RNA within 2 months after end of prior treatment, or who received previous pegIFN-based therapy for <12 weeks and did not discontinue previous therapy due to pegIFN-and/or RBV-related adverse events, or patients who had received non-pegIFN-based therapy (IFN with or without RBV), regardless of prior treatment response.
§ For conservative reasons, the SVR12 rate for the 'other' population was set to the same rate as for treatment-naïve patients.
DAA, direct-acting antiviral agent; HCV, hepatitis C virus; IFN, interferon; pegIFN/RBV, peginterferon+ribavirin; RBV, ribavirin; SVR12, sustained virological response 12 weeks after end of treatment.
Supporting Table 2 Data are mean change from baseline (standard error).
* HCV-SIQv4 OBSS: range 0 (no symptoms) to 100 (maximum severity for all 29 symptoms), mean reduction of ≥10 points is clinically important. † FSS: range 1 (no fatigue) to 7 (severe fatigue), mean reduction of 0.6 points is clinically important.
‡ FSS and CES-D, n=120. § CES-D: range 0 (no depressive symptoms) to 60 (severe depression on 20 symptoms), mean reduction of ≥6 points is clinically important. || EQ-5D VAS: range 0 (worst possible health) to 100 (perfect health), changes from baseline of at least ±8 points are clinically important.
¶ EQ-5D VAS, n=118.
CES-D, Center for Epidemiologic Studies Depression Scale; EQ-5D VAS, EuroQol 5-Dimensions questionnaire Visual Analog Scale; FSS, Fatigue Severity Scale; HCV-SIQv4 OBSS, Hepatitis C Symptom and Impact Questionnaire version 4 Overall Body System Score; QD, once daily; SMV, simeprevir; SOF, sofosbuvir; SVR12, sustained virological response at 12 weeks after end of treatment. 
Data are n (%).
QD, once daily. Data are mean (standard error).
HCV-SIQv4, Hepatitis C Symptom and Impact Questionnaire version 4; QD, once daily.
Supporting Fig. 1 . OPTIMIST-1 study design.
Treatment was to be discontinued in patients with viral breakthrough (confirmed >1.0 log 10 increase in HCV RNA from nadir or confirmed HCV RNA >100 IU/mL in patients who had previously achieved HCV RNA <25 IU/mL).
HCV, hepatitis C virus; QD, once daily; SMV, simeprevir; SOF, sofosbuvir; SVR12, sustained virological response 12 weeks after end of treatment; SVR24, sustained virological response 24 weeks after end of treatment. CES-D, Center for Epidemiologic Studies Depression Scale; EQ-5D VAS, EuroQol 5-Dimensions questionnaire Visual Analog Scale; FSS, Fatigue Severity Scale; FU, follow-up; HCV-SIQv4 OBSS, Hepatitis C Symptom and Impact Questionnaire version 4 Overall Body System Score; SE, standard error; SMV, simeprevir; SOF, sofosbuvir; WK, week.
